| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 55 | 2022 | 544 | 7.070 |
Why?
|
| Carcinoma, Squamous Cell | 50 | 2021 | 628 | 5.340 |
Why?
|
| Quinazolines | 20 | 2015 | 243 | 2.580 |
Why?
|
| Prostatic Neoplasms | 21 | 2021 | 999 | 2.390 |
Why?
|
| ErbB Receptors | 20 | 2020 | 605 | 2.300 |
Why?
|
| Radiotherapy, Intensity-Modulated | 8 | 2018 | 129 | 2.020 |
Why?
|
| Combined Modality Therapy | 44 | 2020 | 1201 | 1.970 |
Why?
|
| Oropharyngeal Neoplasms | 12 | 2019 | 48 | 1.960 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2020 | 1560 | 1.810 |
Why?
|
| Radiotherapy | 13 | 2019 | 185 | 1.660 |
Why?
|
| Radiotherapy, Conformal | 10 | 2015 | 69 | 1.660 |
Why?
|
| Cetuximab | 15 | 2020 | 94 | 1.630 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 15 | 2022 | 1050 | 1.590 |
Why?
|
| Antineoplastic Agents | 28 | 2017 | 2045 | 1.580 |
Why?
|
| Chemoradiotherapy | 16 | 2020 | 208 | 1.450 |
Why?
|
| Brachytherapy | 5 | 2016 | 104 | 1.340 |
Why?
|
| Lung Neoplasms | 17 | 2022 | 2344 | 1.320 |
Why?
|
| Radiosurgery | 11 | 2022 | 321 | 1.300 |
Why?
|
| Diglycerides | 14 | 2016 | 61 | 1.230 |
Why?
|
| Neoplasm Staging | 22 | 2018 | 1282 | 1.160 |
Why?
|
| Radiotherapy Dosage | 22 | 2021 | 251 | 1.140 |
Why?
|
| Neoplasm Proteins | 5 | 2020 | 417 | 0.990 |
Why?
|
| Laryngeal Neoplasms | 5 | 2017 | 31 | 0.970 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2020 | 377 | 0.940 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 7 | 2018 | 124 | 0.880 |
Why?
|
| Phthalazines | 3 | 2020 | 41 | 0.860 |
Why?
|
| Melanoma | 5 | 2018 | 730 | 0.850 |
Why?
|
| Radiation Injuries | 7 | 2021 | 135 | 0.840 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 5 | 2007 | 107 | 0.830 |
Why?
|
| Biomarkers, Tumor | 9 | 2022 | 1161 | 0.820 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2020 | 90 | 0.800 |
Why?
|
| DNA Repair | 4 | 2020 | 210 | 0.790 |
Why?
|
| Diacylglycerol Kinase | 3 | 2016 | 5 | 0.770 |
Why?
|
| Piperidines | 7 | 2015 | 200 | 0.760 |
Why?
|
| Piperazines | 3 | 2020 | 339 | 0.740 |
Why?
|
| Aged | 63 | 2019 | 22107 | 0.740 |
Why?
|
| Thrombin | 9 | 2001 | 147 | 0.730 |
Why?
|
| Immunotherapy | 4 | 2019 | 596 | 0.700 |
Why?
|
| Humans | 142 | 2022 | 129847 | 0.690 |
Why?
|
| Antibodies, Monoclonal | 10 | 2016 | 1368 | 0.690 |
Why?
|
| Neovascularization, Pathologic | 5 | 2006 | 297 | 0.690 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2006 | 218 | 0.680 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 42 | 0.680 |
Why?
|
| Signal Transduction | 24 | 2019 | 4935 | 0.680 |
Why?
|
| Middle Aged | 62 | 2019 | 31177 | 0.670 |
Why?
|
| Cisplatin | 13 | 2020 | 299 | 0.670 |
Why?
|
| Xenograft Model Antitumor Assays | 13 | 2020 | 808 | 0.640 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2016 | 66 | 0.620 |
Why?
|
| Phosphatidylcholines | 8 | 2016 | 145 | 0.620 |
Why?
|
| Mice, Nude | 15 | 2020 | 680 | 0.610 |
Why?
|
| Neoplasms | 10 | 2018 | 2454 | 0.590 |
Why?
|
| Glottis | 2 | 2017 | 19 | 0.590 |
Why?
|
| Organ Sparing Treatments | 2 | 2015 | 32 | 0.590 |
Why?
|
| Survival Rate | 18 | 2019 | 1872 | 0.590 |
Why?
|
| Papillomavirus Infections | 5 | 2022 | 297 | 0.580 |
Why?
|
| Receptor, EphB4 | 4 | 2019 | 36 | 0.580 |
Why?
|
| Stomatitis | 6 | 2021 | 14 | 0.560 |
Why?
|
| Smokers | 1 | 2018 | 140 | 0.550 |
Why?
|
| Mouth Neoplasms | 4 | 2019 | 86 | 0.550 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2020 | 957 | 0.550 |
Why?
|
| Unilamellar Liposomes | 1 | 2016 | 8 | 0.530 |
Why?
|
| Cell Line, Tumor | 23 | 2020 | 3185 | 0.530 |
Why?
|
| Enzyme Assays | 1 | 2016 | 25 | 0.530 |
Why?
|
| Male | 74 | 2021 | 63759 | 0.530 |
Why?
|
| Intracellular Membranes | 1 | 2016 | 83 | 0.520 |
Why?
|
| Prognosis | 21 | 2022 | 3773 | 0.510 |
Why?
|
| Molecular Targeted Therapy | 6 | 2019 | 391 | 0.510 |
Why?
|
| Aged, 80 and over | 25 | 2019 | 7066 | 0.510 |
Why?
|
| Papillomaviridae | 7 | 2019 | 112 | 0.500 |
Why?
|
| Animals | 57 | 2021 | 35409 | 0.500 |
Why?
|
| Proton Therapy | 2 | 2017 | 12 | 0.500 |
Why?
|
| Skin Neoplasms | 2 | 2015 | 830 | 0.500 |
Why?
|
| Proportional Hazards Models | 15 | 2019 | 1199 | 0.490 |
Why?
|
| Radiation Oncology | 4 | 2018 | 75 | 0.490 |
Why?
|
| Mucositis | 4 | 2021 | 19 | 0.480 |
Why?
|
| Submandibular Gland | 1 | 2015 | 19 | 0.480 |
Why?
|
| Radiation Tolerance | 6 | 2019 | 98 | 0.480 |
Why?
|
| Medically Uninsured | 1 | 2015 | 128 | 0.470 |
Why?
|
| Prostate-Specific Antigen | 7 | 2016 | 160 | 0.470 |
Why?
|
| Female | 68 | 2021 | 68829 | 0.450 |
Why?
|
| Ephrin-B2 | 3 | 2019 | 50 | 0.450 |
Why?
|
| Treatment Outcome | 28 | 2019 | 10241 | 0.450 |
Why?
|
| Nuclear Envelope | 3 | 2000 | 28 | 0.440 |
Why?
|
| Adenosine Triphosphate | 1 | 2016 | 482 | 0.440 |
Why?
|
| Cell Nucleus | 4 | 2004 | 590 | 0.440 |
Why?
|
| Esophagus | 2 | 2012 | 251 | 0.420 |
Why?
|
| Disease-Free Survival | 15 | 2017 | 647 | 0.420 |
Why?
|
| Insurance, Health | 1 | 2015 | 269 | 0.420 |
Why?
|
| Epidermal Growth Factor | 8 | 2005 | 170 | 0.410 |
Why?
|
| Tumor Microenvironment | 4 | 2021 | 627 | 0.400 |
Why?
|
| Clinical Trials as Topic | 9 | 2022 | 1005 | 0.400 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2019 | 851 | 0.400 |
Why?
|
| Androgen Antagonists | 4 | 2021 | 79 | 0.400 |
Why?
|
| Phospholipids | 7 | 2000 | 216 | 0.390 |
Why?
|
| Esophagitis | 1 | 2012 | 67 | 0.380 |
Why?
|
| Phosphatidylinositols | 7 | 2000 | 57 | 0.380 |
Why?
|
| Remote Consultation | 1 | 2012 | 46 | 0.370 |
Why?
|
| Mice | 32 | 2021 | 16983 | 0.370 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2020 | 1327 | 0.370 |
Why?
|
| Medicaid | 1 | 2015 | 433 | 0.370 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2022 | 181 | 0.360 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2019 | 39 | 0.360 |
Why?
|
| Facial Neoplasms | 1 | 2011 | 18 | 0.360 |
Why?
|
| Adult | 35 | 2019 | 35634 | 0.350 |
Why?
|
| Follow-Up Studies | 13 | 2019 | 4896 | 0.350 |
Why?
|
| Lymph Nodes | 6 | 2019 | 471 | 0.350 |
Why?
|
| Urinary Bladder | 2 | 2010 | 176 | 0.340 |
Why?
|
| Peptides, Cyclic | 3 | 2020 | 256 | 0.340 |
Why?
|
| Comparative Effectiveness Research | 1 | 2011 | 151 | 0.330 |
Why?
|
| SEER Program | 8 | 2019 | 202 | 0.330 |
Why?
|
| Glycerides | 5 | 1993 | 20 | 0.330 |
Why?
|
| Boronic Acids | 1 | 2010 | 37 | 0.330 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2009 | 78 | 0.320 |
Why?
|
| B7-H1 Antigen | 3 | 2021 | 198 | 0.320 |
Why?
|
| Retrospective Studies | 20 | 2021 | 14553 | 0.320 |
Why?
|
| Smad4 Protein | 2 | 2020 | 38 | 0.320 |
Why?
|
| Propensity Score | 5 | 2017 | 266 | 0.310 |
Why?
|
| Pyrazines | 1 | 2010 | 87 | 0.310 |
Why?
|
| Pancreatic Neoplasms | 3 | 2019 | 879 | 0.310 |
Why?
|
| Adenoma | 1 | 2011 | 213 | 0.310 |
Why?
|
| Counseling | 1 | 2012 | 386 | 0.310 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2011 | 178 | 0.310 |
Why?
|
| Neoplasm Grading | 5 | 2016 | 283 | 0.300 |
Why?
|
| Smad7 Protein | 3 | 2021 | 18 | 0.300 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2017 | 208 | 0.300 |
Why?
|
| ras Proteins | 1 | 2009 | 143 | 0.290 |
Why?
|
| Feasibility Studies | 5 | 2015 | 870 | 0.290 |
Why?
|
| United States | 18 | 2019 | 13913 | 0.280 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2019 | 373 | 0.280 |
Why?
|
| Fibroblasts | 8 | 2001 | 954 | 0.280 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2009 | 634 | 0.280 |
Why?
|
| Nomograms | 2 | 2018 | 47 | 0.280 |
Why?
|
| Organs at Risk | 4 | 2015 | 31 | 0.280 |
Why?
|
| Protein-Tyrosine Kinases | 6 | 2015 | 431 | 0.270 |
Why?
|
| Cricetinae | 9 | 2001 | 280 | 0.270 |
Why?
|
| Organophosphorus Compounds | 2 | 2005 | 78 | 0.270 |
Why?
|
| Survival Analysis | 9 | 2019 | 1271 | 0.270 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2019 | 200 | 0.270 |
Why?
|
| Kidney Neoplasms | 1 | 2011 | 347 | 0.270 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2006 | 13 | 0.260 |
Why?
|
| Mesoderm | 1 | 2007 | 138 | 0.260 |
Why?
|
| Neoplasm Metastasis | 4 | 2018 | 610 | 0.250 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 763 | 0.250 |
Why?
|
| Intestines | 1 | 2009 | 350 | 0.250 |
Why?
|
| Neoplasms, Experimental | 3 | 2015 | 171 | 0.250 |
Why?
|
| Radiation, Ionizing | 7 | 2012 | 77 | 0.240 |
Why?
|
| Technology, Radiologic | 1 | 2005 | 6 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2007 | 753 | 0.240 |
Why?
|
| Mitogens | 4 | 2000 | 61 | 0.240 |
Why?
|
| Dose-Response Relationship, Radiation | 5 | 2020 | 133 | 0.230 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2016 | 34 | 0.230 |
Why?
|
| Maximum Tolerated Dose | 3 | 2015 | 193 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2014 | 756 | 0.220 |
Why?
|
| Induction Chemotherapy | 2 | 2017 | 70 | 0.220 |
Why?
|
| Kinetics | 9 | 2016 | 1645 | 0.220 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2015 | 226 | 0.220 |
Why?
|
| Stress, Psychological | 1 | 2012 | 1070 | 0.220 |
Why?
|
| Type C Phospholipases | 2 | 1997 | 74 | 0.220 |
Why?
|
| Transforming Growth Factor beta | 3 | 2021 | 462 | 0.210 |
Why?
|
| Immunohistochemistry | 9 | 2019 | 1690 | 0.210 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 379 | 0.210 |
Why?
|
| Mutation | 6 | 2013 | 3706 | 0.210 |
Why?
|
| Apoptosis | 9 | 2020 | 2489 | 0.200 |
Why?
|
| Risk Assessment | 6 | 2019 | 3269 | 0.200 |
Why?
|
| Disease Models, Animal | 9 | 2020 | 4077 | 0.200 |
Why?
|
| Phosphatidylserines | 3 | 2016 | 88 | 0.200 |
Why?
|
| Tonsillar Neoplasms | 2 | 2015 | 8 | 0.200 |
Why?
|
| Drug Synergism | 3 | 2020 | 370 | 0.200 |
Why?
|
| Receptors, Thrombin | 2 | 2000 | 13 | 0.200 |
Why?
|
| Taxoids | 4 | 2015 | 98 | 0.200 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2017 | 259 | 0.190 |
Why?
|
| Circulating Tumor DNA | 1 | 2022 | 28 | 0.190 |
Why?
|
| Hydrolysis | 7 | 2000 | 186 | 0.190 |
Why?
|
| Membrane Lipids | 2 | 1994 | 91 | 0.190 |
Why?
|
| Cricetulus | 6 | 2000 | 107 | 0.190 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2019 | 34 | 0.190 |
Why?
|
| Prostatectomy | 3 | 2014 | 103 | 0.190 |
Why?
|
| Databases, Factual | 6 | 2017 | 1269 | 0.190 |
Why?
|
| Transcriptome | 2 | 2018 | 875 | 0.190 |
Why?
|
| DNA, Neoplasm | 2 | 2020 | 154 | 0.180 |
Why?
|
| Paclitaxel | 3 | 2012 | 218 | 0.180 |
Why?
|
| Enzyme Inhibitors | 5 | 2005 | 827 | 0.180 |
Why?
|
| Rectum | 2 | 2014 | 170 | 0.180 |
Why?
|
| Time Factors | 10 | 2017 | 6550 | 0.180 |
Why?
|
| Keratinocytes | 3 | 2017 | 244 | 0.180 |
Why?
|
| Models, Biological | 6 | 2018 | 1724 | 0.180 |
Why?
|
| Epithelial Cells | 1 | 2007 | 1063 | 0.180 |
Why?
|
| National Cancer Institute (U.S.) | 5 | 2019 | 43 | 0.170 |
Why?
|
| DNA End-Joining Repair | 1 | 2020 | 18 | 0.170 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 69 | 0.170 |
Why?
|
| Mice, Inbred BALB C | 6 | 2019 | 1248 | 0.170 |
Why?
|
| Neoplasm Transplantation | 4 | 2018 | 253 | 0.170 |
Why?
|
| Clone Cells | 1 | 2020 | 262 | 0.170 |
Why?
|
| Cohort Studies | 7 | 2021 | 5444 | 0.170 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2017 | 41 | 0.170 |
Why?
|
| Radioimmunotherapy | 1 | 2019 | 16 | 0.160 |
Why?
|
| Radiography | 4 | 2010 | 800 | 0.160 |
Why?
|
| Cell Proliferation | 8 | 2020 | 2378 | 0.160 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2020 | 41 | 0.160 |
Why?
|
| Drosophila melanogaster | 2 | 2012 | 211 | 0.160 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 2017 | 16 | 0.160 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2017 | 17 | 0.160 |
Why?
|
| Phosphorylation | 4 | 2016 | 1716 | 0.160 |
Why?
|
| Chemokines, CXC | 1 | 2019 | 70 | 0.160 |
Why?
|
| Lymphocyte Depletion | 1 | 2019 | 134 | 0.160 |
Why?
|
| Tumor Escape | 1 | 2019 | 39 | 0.160 |
Why?
|
| Phosphatidylethanolamines | 2 | 2016 | 74 | 0.160 |
Why?
|
| Tongue Neoplasms | 2 | 2009 | 24 | 0.150 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 58 | 0.150 |
Why?
|
| Receptor, EphB3 | 1 | 2018 | 4 | 0.150 |
Why?
|
| Morpholines | 2 | 2018 | 123 | 0.150 |
Why?
|
| Alphapapillomavirus | 2 | 2016 | 39 | 0.150 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2018 | 30 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2010 | 2016 | 0.150 |
Why?
|
| Liver Neoplasms | 2 | 2018 | 636 | 0.150 |
Why?
|
| Chromosome Aberrations | 1 | 2019 | 140 | 0.150 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 81 | 0.150 |
Why?
|
| Hyperlipidemias | 1 | 2019 | 127 | 0.150 |
Why?
|
| Patient Selection | 2 | 2019 | 660 | 0.140 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 194 | 0.140 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 87 | 0.140 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2018 | 35 | 0.140 |
Why?
|
| Up-Regulation | 4 | 2019 | 836 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2006 | 1284 | 0.140 |
Why?
|
| Aminopyridines | 1 | 2018 | 98 | 0.140 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2018 | 22 | 0.140 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2017 | 11 | 0.140 |
Why?
|
| Organ Specificity | 1 | 2018 | 295 | 0.140 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2017 | 10 | 0.140 |
Why?
|
| Gene Deletion | 1 | 2019 | 380 | 0.140 |
Why?
|
| Nose Neoplasms | 1 | 2017 | 20 | 0.140 |
Why?
|
| Cell Line | 8 | 2001 | 2780 | 0.140 |
Why?
|
| Cell Cycle | 5 | 2021 | 583 | 0.140 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2017 | 23 | 0.140 |
Why?
|
| Phospholipase D | 2 | 1997 | 8 | 0.130 |
Why?
|
| Transplantation, Heterologous | 4 | 2006 | 191 | 0.130 |
Why?
|
| Prospective Studies | 7 | 2019 | 7158 | 0.130 |
Why?
|
| GTP-Binding Proteins | 1 | 1997 | 158 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 2 | 2008 | 106 | 0.130 |
Why?
|
| Deoxycytidine | 2 | 2008 | 164 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 204 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2007 | 84 | 0.130 |
Why?
|
| Radiodermatitis | 1 | 2016 | 8 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 232 | 0.130 |
Why?
|
| Drug Eruptions | 1 | 2016 | 27 | 0.130 |
Why?
|
| Antibodies | 1 | 2018 | 399 | 0.130 |
Why?
|
| Cell Movement | 2 | 2018 | 950 | 0.130 |
Why?
|
| Lymphatic Metastasis | 5 | 2019 | 320 | 0.120 |
Why?
|
| Database Management Systems | 1 | 2016 | 48 | 0.120 |
Why?
|
| Skin Ulcer | 1 | 2015 | 13 | 0.120 |
Why?
|
| Isoenzymes | 1 | 2016 | 301 | 0.120 |
Why?
|
| Wound Healing | 1 | 2018 | 308 | 0.120 |
Why?
|
| Radiometry | 1 | 2015 | 48 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 378 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2012 | 191 | 0.120 |
Why?
|
| Surface Properties | 1 | 2016 | 400 | 0.120 |
Why?
|
| Neutrophils | 2 | 2019 | 1209 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1997 | 319 | 0.120 |
Why?
|
| Deglutition Disorders | 2 | 2016 | 133 | 0.120 |
Why?
|
| Enzyme Activation | 4 | 2001 | 813 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 55 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2017 | 1368 | 0.120 |
Why?
|
| Mammals | 1 | 2016 | 274 | 0.120 |
Why?
|
| Radiation Protection | 1 | 2015 | 38 | 0.120 |
Why?
|
| Blotting, Western | 5 | 2013 | 1204 | 0.120 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 77 | 0.120 |
Why?
|
| Analysis of Variance | 5 | 2019 | 1291 | 0.110 |
Why?
|
| Colorectal Neoplasms | 2 | 2019 | 748 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 484 | 0.110 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 88 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 430 | 0.110 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 311 | 0.110 |
Why?
|
| Stromal Cells | 1 | 2014 | 106 | 0.110 |
Why?
|
| Protein Binding | 2 | 2016 | 2123 | 0.110 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2011 | 85 | 0.110 |
Why?
|
| Tumor Burden | 4 | 2018 | 287 | 0.110 |
Why?
|
| Cell Division | 3 | 2007 | 790 | 0.110 |
Why?
|
| Quality of Life | 4 | 2018 | 2695 | 0.110 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 1990 | 89 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 855 | 0.100 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 1501 | 0.100 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 188 | 0.100 |
Why?
|
| DNA Replication | 4 | 2000 | 225 | 0.100 |
Why?
|
| Colorado | 2 | 2015 | 4410 | 0.100 |
Why?
|
| DNA, Viral | 2 | 2015 | 347 | 0.100 |
Why?
|
| Salvage Therapy | 2 | 2011 | 136 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 4 | 2020 | 931 | 0.100 |
Why?
|
| Phosphatidic Acids | 1 | 1992 | 9 | 0.100 |
Why?
|
| Radiation-Protective Agents | 1 | 2012 | 26 | 0.100 |
Why?
|
| G1 Phase | 2 | 2005 | 69 | 0.100 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2016 | 530 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2017 | 606 | 0.100 |
Why?
|
| Brain Neoplasms | 2 | 2018 | 1149 | 0.100 |
Why?
|
| Larynx | 1 | 2012 | 60 | 0.100 |
Why?
|
| Metalloporphyrins | 1 | 2012 | 101 | 0.100 |
Why?
|
| Diarrhea | 2 | 2010 | 181 | 0.090 |
Why?
|
| Adenocarcinoma | 2 | 2009 | 893 | 0.090 |
Why?
|
| Radiation Pneumonitis | 1 | 2011 | 28 | 0.090 |
Why?
|
| Carbachol | 1 | 1991 | 20 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2010 | 886 | 0.090 |
Why?
|
| Device Removal | 1 | 2012 | 136 | 0.090 |
Why?
|
| Telephone | 1 | 2012 | 168 | 0.090 |
Why?
|
| Autocrine Communication | 1 | 2011 | 42 | 0.090 |
Why?
|
| Maytansine | 1 | 2011 | 16 | 0.090 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2011 | 65 | 0.090 |
Why?
|
| Risk Factors | 6 | 2019 | 9801 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 766 | 0.090 |
Why?
|
| Mohs Surgery | 1 | 2011 | 25 | 0.090 |
Why?
|
| Nerve Growth Factors | 1 | 1991 | 75 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2015 | 1597 | 0.090 |
Why?
|
| Second Messenger Systems | 1 | 1990 | 33 | 0.090 |
Why?
|
| DNA Damage | 3 | 2020 | 383 | 0.090 |
Why?
|
| Flow Cytometry | 3 | 2019 | 1160 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 379 | 0.080 |
Why?
|
| Triazines | 1 | 2010 | 38 | 0.080 |
Why?
|
| Palliative Care | 2 | 2010 | 706 | 0.080 |
Why?
|
| Caspase 3 | 1 | 2011 | 244 | 0.080 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2011 | 88 | 0.080 |
Why?
|
| Arachidonic Acid | 3 | 1999 | 115 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2019 | 307 | 0.080 |
Why?
|
| Bortezomib | 1 | 2010 | 45 | 0.080 |
Why?
|
| Lymphopenia | 1 | 2010 | 60 | 0.080 |
Why?
|
| Nausea | 1 | 2010 | 111 | 0.080 |
Why?
|
| Prostaglandin D2 | 1 | 2009 | 22 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2015 | 94 | 0.080 |
Why?
|
| Lymphatic Irradiation | 1 | 2009 | 9 | 0.080 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 234 | 0.080 |
Why?
|
| Urination Disorders | 1 | 2009 | 13 | 0.080 |
Why?
|
| Artifacts | 1 | 2010 | 127 | 0.080 |
Why?
|
| Gene Expression Profiling | 4 | 2019 | 1686 | 0.080 |
Why?
|
| Neutropenia | 1 | 2010 | 137 | 0.080 |
Why?
|
| Radioisotopes | 1 | 2009 | 31 | 0.080 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2009 | 66 | 0.080 |
Why?
|
| Cystitis | 1 | 2009 | 22 | 0.080 |
Why?
|
| Palladium | 1 | 2009 | 15 | 0.080 |
Why?
|
| Exanthema | 1 | 2009 | 74 | 0.080 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 402 | 0.080 |
Why?
|
| Antioxidants | 1 | 2012 | 558 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 1033 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 756 | 0.080 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2019 | 220 | 0.070 |
Why?
|
| Carcinoma | 2 | 2011 | 213 | 0.070 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 133 | 0.070 |
Why?
|
| Iodine Radioisotopes | 1 | 2009 | 143 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 2 | 2015 | 325 | 0.070 |
Why?
|
| Heterografts | 2 | 2019 | 134 | 0.070 |
Why?
|
| Pelvis | 1 | 2009 | 104 | 0.070 |
Why?
|
| Social Support | 1 | 2012 | 587 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 639 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2012 | 878 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 2545 | 0.070 |
Why?
|
| Fatigue | 1 | 2010 | 319 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2008 | 59 | 0.070 |
Why?
|
| Glutathione | 1 | 2009 | 349 | 0.070 |
Why?
|
| Adaptation, Psychological | 1 | 2012 | 618 | 0.070 |
Why?
|
| Fluorouracil | 1 | 2008 | 197 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 2 | 2005 | 211 | 0.070 |
Why?
|
| Predictive Value of Tests | 4 | 2017 | 1951 | 0.070 |
Why?
|
| Bone Neoplasms | 2 | 2015 | 229 | 0.070 |
Why?
|
| Rectal Neoplasms | 1 | 2008 | 134 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 317 | 0.070 |
Why?
|
| Positron-Emission Tomography | 2 | 2006 | 282 | 0.070 |
Why?
|
| Cortactin | 1 | 2006 | 7 | 0.070 |
Why?
|
| Actin-Related Protein 2-3 Complex | 1 | 2006 | 8 | 0.070 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1877 | 0.070 |
Why?
|
| Respiratory Mucosa | 1 | 2009 | 310 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 56 | 0.060 |
Why?
|
| Axilla | 1 | 2006 | 46 | 0.060 |
Why?
|
| Erythropoietin | 1 | 2007 | 88 | 0.060 |
Why?
|
| Nutritional Support | 1 | 2006 | 32 | 0.060 |
Why?
|
| Xanthones | 1 | 2005 | 6 | 0.060 |
Why?
|
| RNA Interference | 2 | 2018 | 451 | 0.060 |
Why?
|
| Protein Kinase C | 2 | 2019 | 262 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2006 | 186 | 0.060 |
Why?
|
| Neutrons | 1 | 2005 | 10 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 530 | 0.060 |
Why?
|
| Particle Accelerators | 1 | 2005 | 10 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 1847 | 0.060 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2005 | 15 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2006 | 295 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2005 | 528 | 0.060 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2004 | 27 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2013 | 362 | 0.060 |
Why?
|
| Electrons | 1 | 2005 | 77 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 5085 | 0.060 |
Why?
|
| Mitosis | 2 | 2011 | 180 | 0.060 |
Why?
|
| Ki-67 Antigen | 1 | 2004 | 108 | 0.060 |
Why?
|
| Trypanosoma | 2 | 1994 | 7 | 0.050 |
Why?
|
| Glycosylphosphatidylinositols | 2 | 1994 | 11 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 5468 | 0.050 |
Why?
|
| Algorithms | 2 | 2015 | 1617 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 1214 | 0.050 |
Why?
|
| Necrosis | 1 | 2004 | 234 | 0.050 |
Why?
|
| Disease Progression | 3 | 2018 | 2628 | 0.050 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2003 | 14 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2009 | 640 | 0.050 |
Why?
|
| Etoposide | 2 | 2015 | 148 | 0.050 |
Why?
|
| Young Adult | 2 | 2017 | 12467 | 0.050 |
Why?
|
| Genes, erbB-1 | 1 | 2002 | 17 | 0.050 |
Why?
|
| Biological Products | 2 | 2019 | 207 | 0.050 |
Why?
|
| Biomarkers | 3 | 2019 | 3971 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 3089 | 0.050 |
Why?
|
| Glioblastoma | 1 | 2005 | 322 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 1434 | 0.050 |
Why?
|
| Gene Products, tat | 1 | 2021 | 22 | 0.050 |
Why?
|
| Macrophages | 2 | 2019 | 1489 | 0.050 |
Why?
|
| Protein Biosynthesis | 2 | 2015 | 406 | 0.050 |
Why?
|
| Chemoprevention | 1 | 2002 | 91 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2019 | 312 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2001 | 113 | 0.040 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2001 | 88 | 0.040 |
Why?
|
| Logistic Models | 2 | 2017 | 1989 | 0.040 |
Why?
|
| Dogs | 1 | 2021 | 385 | 0.040 |
Why?
|
| Cyclin D1 | 1 | 2000 | 62 | 0.040 |
Why?
|
| Incidence | 3 | 2016 | 2646 | 0.040 |
Why?
|
| Chromatography, Gas | 2 | 1990 | 32 | 0.040 |
Why?
|
| Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.040 |
Why?
|
| Androgens | 1 | 2021 | 177 | 0.040 |
Why?
|
| Mass Screening | 1 | 2008 | 1192 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2018 | 2724 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 2511 | 0.040 |
Why?
|
| Receptor, PAR-1 | 1 | 2000 | 22 | 0.040 |
Why?
|
| Lipids | 1 | 2004 | 628 | 0.040 |
Why?
|
| Pain | 1 | 2006 | 791 | 0.040 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 82 | 0.040 |
Why?
|
| Cell Death | 2 | 2011 | 353 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2002 | 787 | 0.040 |
Why?
|
| Choline | 2 | 1991 | 122 | 0.040 |
Why?
|
| Pyrimidine Nucleosides | 1 | 2019 | 1 | 0.040 |
Why?
|
| Immunologic Factors | 2 | 2016 | 229 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2000 | 126 | 0.040 |
Why?
|
| Enteropeptidase | 1 | 1999 | 2 | 0.040 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2019 | 45 | 0.040 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2019 | 158 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 184 | 0.040 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 64 | 0.040 |
Why?
|
| Luminescence | 1 | 2018 | 37 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2015 | 941 | 0.040 |
Why?
|
| Herpesvirus 1, Human | 1 | 2019 | 86 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 902 | 0.040 |
Why?
|
| Rats | 3 | 2012 | 5487 | 0.040 |
Why?
|
| DNA Primers | 1 | 1999 | 508 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 164 | 0.040 |
Why?
|
| Choline Kinase | 1 | 1997 | 3 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2018 | 377 | 0.040 |
Why?
|
| Phosphatidate Phosphatase | 1 | 1997 | 5 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2018 | 92 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 41 | 0.030 |
Why?
|
| Cell Transformation, Viral | 1 | 2017 | 25 | 0.030 |
Why?
|
| Phospholipases A2 | 1 | 1997 | 79 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 1997 | 18 | 0.030 |
Why?
|
| Transducin | 1 | 1997 | 42 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2019 | 349 | 0.030 |
Why?
|
| Cells, Cultured | 4 | 2000 | 4102 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 422 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 148 | 0.030 |
Why?
|
| Research Design | 1 | 2003 | 1045 | 0.030 |
Why?
|
| Phospholipases A | 1 | 1997 | 99 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2016 | 32 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2017 | 38 | 0.030 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2017 | 37 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1997 | 112 | 0.030 |
Why?
|
| Oligopeptides | 1 | 1999 | 260 | 0.030 |
Why?
|
| Variant Surface Glycoproteins, Trypanosoma | 2 | 1994 | 2 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 45 | 0.030 |
Why?
|
| CpG Islands | 1 | 2017 | 152 | 0.030 |
Why?
|
| Laryngectomy | 1 | 2016 | 15 | 0.030 |
Why?
|
| Viral Core Proteins | 1 | 2016 | 21 | 0.030 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2015 | 3 | 0.030 |
Why?
|
| Absorption, Radiation | 1 | 2015 | 3 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2017 | 207 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 117 | 0.030 |
Why?
|
| Skin | 2 | 2012 | 725 | 0.030 |
Why?
|
| Neck Dissection | 1 | 2015 | 16 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2017 | 220 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2017 | 377 | 0.030 |
Why?
|
| Urothelium | 1 | 2015 | 37 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 2739 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2016 | 306 | 0.030 |
Why?
|
| Base Sequence | 1 | 1999 | 2142 | 0.030 |
Why?
|
| Age Factors | 2 | 2016 | 3161 | 0.030 |
Why?
|
| Phosphatidylinositol Diacylglycerol-Lyase | 1 | 1994 | 4 | 0.030 |
Why?
|
| Veratrum Alkaloids | 1 | 2014 | 19 | 0.030 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2014 | 23 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 1999 | 2057 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 38 | 0.030 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 1994 | 46 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 1994 | 159 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 590 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2015 | 160 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2015 | 128 | 0.030 |
Why?
|
| Fatty Acids | 2 | 1994 | 427 | 0.030 |
Why?
|
| Cell Fractionation | 1 | 1994 | 56 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 2135 | 0.030 |
Why?
|
| Gene Expression | 1 | 2019 | 1465 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2015 | 611 | 0.030 |
Why?
|
| Smoking | 2 | 2014 | 1502 | 0.030 |
Why?
|
| Glycerol | 1 | 1994 | 92 | 0.030 |
Why?
|
| Medicare | 1 | 2019 | 719 | 0.030 |
Why?
|
| Myristic Acids | 1 | 1993 | 8 | 0.030 |
Why?
|
| Receptor, Notch2 | 1 | 2013 | 15 | 0.030 |
Why?
|
| Gonanes | 1 | 2013 | 27 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 3397 | 0.030 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2013 | 32 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 212 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2013 | 54 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2013 | 62 | 0.030 |
Why?
|
| Neuropeptides | 1 | 2013 | 72 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 1 | 1992 | 23 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 1213 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 201 | 0.020 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2013 | 58 | 0.020 |
Why?
|
| Autoradiography | 1 | 1992 | 74 | 0.020 |
Why?
|
| Penis | 1 | 2012 | 35 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 615 | 0.020 |
Why?
|
| Erectile Dysfunction | 1 | 2012 | 39 | 0.020 |
Why?
|
| Testis | 1 | 2012 | 144 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2015 | 624 | 0.020 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2011 | 18 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 398 | 0.020 |
Why?
|
| Group VI Phospholipases A2 | 1 | 2011 | 6 | 0.020 |
Why?
|
| Glioma | 1 | 2015 | 351 | 0.020 |
Why?
|
| Thymidine | 1 | 1991 | 60 | 0.020 |
Why?
|
| Carboplatin | 1 | 2011 | 139 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2011 | 76 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 1551 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 201 | 0.020 |
Why?
|
| Camptothecin | 1 | 2011 | 110 | 0.020 |
Why?
|
| Hirudins | 1 | 1991 | 53 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2011 | 187 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 1994 | 503 | 0.020 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2010 | 30 | 0.020 |
Why?
|
| Chymotrypsin | 1 | 1990 | 19 | 0.020 |
Why?
|
| Spindle Apparatus | 1 | 2011 | 95 | 0.020 |
Why?
|
| Larva | 1 | 2011 | 215 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 70 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2010 | 70 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 903 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 2564 | 0.020 |
Why?
|
| tert-Butylhydroperoxide | 1 | 2009 | 10 | 0.020 |
Why?
|
| Organ Size | 1 | 2010 | 456 | 0.020 |
Why?
|
| Cytoprotection | 1 | 2009 | 56 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2013 | 666 | 0.020 |
Why?
|
| Gastrostomy | 1 | 2010 | 109 | 0.020 |
Why?
|
| Phenotype | 1 | 1997 | 3062 | 0.020 |
Why?
|
| Computational Biology | 1 | 2013 | 594 | 0.020 |
Why?
|
| Inositol Phosphates | 1 | 1988 | 23 | 0.020 |
Why?
|
| Inositol | 1 | 1988 | 26 | 0.020 |
Why?
|
| Neck | 1 | 2009 | 95 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 371 | 0.020 |
Why?
|
| Premedication | 1 | 2008 | 42 | 0.020 |
Why?
|
| Capecitabine | 1 | 2008 | 45 | 0.020 |
Why?
|
| Xerostomia | 1 | 2008 | 17 | 0.020 |
Why?
|
| Arachidonic Acids | 1 | 1988 | 59 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2010 | 244 | 0.020 |
Why?
|
| Movement | 1 | 2010 | 270 | 0.020 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2007 | 4 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 1903 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2009 | 162 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 91 | 0.020 |
Why?
|
| Adolescent | 2 | 2017 | 20451 | 0.020 |
Why?
|
| Ethanol | 1 | 1992 | 591 | 0.020 |
Why?
|
| Remission Induction | 1 | 2008 | 274 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 318 | 0.020 |
Why?
|
| Hemoglobin A | 1 | 2007 | 22 | 0.020 |
Why?
|
| Health Transition | 1 | 2007 | 7 | 0.020 |
Why?
|
| Deoxycytidine Kinase | 1 | 2006 | 3 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2011 | 503 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2009 | 585 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2012 | 2403 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 187 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2007 | 89 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2014 | 1645 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 2104 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 2008 | 186 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 2888 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2006 | 20 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2006 | 103 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2017 | 5772 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 1441 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 549 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 860 | 0.020 |
Why?
|
| Laminin | 1 | 2005 | 68 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2006 | 499 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2005 | 109 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2007 | 268 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2005 | 331 | 0.010 |
Why?
|
| Actins | 1 | 2006 | 410 | 0.010 |
Why?
|
| Transfection | 1 | 2006 | 918 | 0.010 |
Why?
|
| Global Health | 1 | 2007 | 329 | 0.010 |
Why?
|
| Stearic Acids | 2 | 1994 | 15 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 1092 | 0.010 |
Why?
|
| Infant | 1 | 2017 | 9018 | 0.010 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 253 | 0.010 |
Why?
|
| Collagen | 1 | 2005 | 438 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2008 | 749 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2007 | 759 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2002 | 42 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2009 | 1264 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2017 | 10522 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 232 | 0.010 |
Why?
|
| Weight Loss | 1 | 2006 | 740 | 0.010 |
Why?
|
| Chromones | 1 | 2000 | 45 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2002 | 434 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2000 | 44 | 0.010 |
Why?
|
| Child | 1 | 2017 | 20962 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1980 | 734 | 0.010 |
Why?
|
| Peptides | 1 | 1980 | 926 | 0.010 |
Why?
|
| Glycolipids | 1 | 1994 | 42 | 0.010 |
Why?
|
| Radioisotope Dilution Technique | 1 | 1993 | 13 | 0.010 |
Why?
|
| Tritium | 1 | 1993 | 75 | 0.010 |
Why?
|
| Acetic Acid | 1 | 1993 | 18 | 0.010 |
Why?
|
| Myristic Acid | 1 | 1993 | 10 | 0.010 |
Why?
|
| DNA | 1 | 1980 | 1406 | 0.010 |
Why?
|
| Acetates | 1 | 1993 | 100 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1980 | 381 | 0.000 |
Why?
|